{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:46:46Z","timestamp":1772135206784,"version":"3.50.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI150478"],"award-info":[{"award-number":["R01AI150478"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    APOBEC3 proteins (A3s) are enzymes that catalyze\u00a0the deamination of cytidine to uridine in single-stranded DNA (ssDNA) substrates, thus playing a key role in innate antiviral immunity. However, the\u00a0APOBEC3 family has also been linked to many mutational signatures in cancer cells, which has led to an\u00a0intense interest to develop inhibitors of A3\u2019s catalytic activity as therapeutics as well as tools to study A3\u2019s biochemistry, structure, and cellular function. Recent studies have shown that ssDNA containing 2\u2032-deoxy-zebularine (dZ-ssDNA) is an inhibitor of A3s such as A3A, A3B, and A3G, although\u00a0the atomic determinants of this activity\u00a0have remained unknown. To fill this knowledge gap, we determined a 1.5\u2009\u00c5 resolution structure of a dZ-ssDNA inhibitor bound to active A3G. The crystal structure revealed that the activated dZ-H\n                    <jats:sub>2<\/jats:sub>\n                    O mimics the transition state by coordinating the active site Zn\n                    <jats:sup>2+<\/jats:sup>\n                    and engaging in additional stabilizing interactions, such as the one with the catalytic residue E259. Therefore, this structure allowed us to capture a snapshot of the A3\u2019s transition state and suggests that developing transition-state mimicking inhibitors may provide a new opportunity to design more targeted molecules for A3s in the future.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-34752-1","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T12:04:02Z","timestamp":1668859442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Structure of the catalytically active APOBEC3G bound to a DNA oligonucleotide inhibitor reveals tetrahedral geometry of the transition state"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-1025","authenticated-orcid":false,"given":"Atanu","family":"Maiti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-2598","authenticated-orcid":false,"given":"Adam K.","family":"Hedger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2055-5180","authenticated-orcid":false,"given":"Wazo","family":"Myint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanivilasini","family":"Balachandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-1734","authenticated-orcid":false,"given":"Jonathan K.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2270-6613","authenticated-orcid":false,"given":"Celia A.","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-6157","authenticated-orcid":false,"given":"Hiroshi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"34752_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nri1489","volume":"4","author":"RS Harris","year":"2004","unstructured":"Harris, R. S. & Liddament, M. T. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4, 868\u2013877 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"34752_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/molbev\/msi026","volume":"22","author":"SG Conticello","year":"2005","unstructured":"Conticello, S. G., Thomas, C. J., Petersen-Mahrt, S. K. & Neuberger, M. S. Evolution of the AID\/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22, 367\u2013377 (2005).","journal-title":"Mol. Biol. Evol."},{"key":"34752_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/bies.950150106","volume":"15","author":"L Chan","year":"1993","unstructured":"Chan, L. RNA editing: exploring one mode with apolipoprotein B mRNA. Bioessays 15, 33\u201341 (1993).","journal-title":"Bioessays"},{"key":"34752_CR4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1126\/science.8511591","volume":"260","author":"B Teng","year":"1993","unstructured":"Teng, B., Burant, C. F. & Davidson, N. O. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260, 1816\u20131819 (1993).","journal-title":"Science"},{"key":"34752_CR5","doi-asserted-by":"publisher","first-page":"20709","DOI":"10.1016\/S0021-9258(19)36836-X","volume":"268","author":"N Navaratnam","year":"1993","unstructured":"Navaratnam, N. et al. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J. Biol. Chem. 268, 20709\u201320712 (1993).","journal-title":"J. Biol. Chem."},{"key":"34752_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1098\/rstb.2008.0185","volume":"364","author":"MH Malim","year":"2009","unstructured":"Malim, M. H. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364, 675\u2013687 (2009).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"34752_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fmicb.2014.00450","volume":"5","author":"Y Feng","year":"2014","unstructured":"Feng, Y., Baig, T. T., Love, R. P. & Chelico, L. Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol. 5, 450 (2014).","journal-title":"Front Microbiol."},{"key":"34752_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0065-2776(06)94002-4","volume":"94","author":"SG Conticello","year":"2007","unstructured":"Conticello, S. G., Langlois, M. A., Yang, Z. & Neuberger, M. S. DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv. Immunol. 94, 37\u201373 (2007).","journal-title":"Adv. Immunol."},{"key":"34752_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nature00939","volume":"418","author":"AM Sheehy","year":"2002","unstructured":"Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646\u2013650 (2002).","journal-title":"Nature"},{"key":"34752_CR10","doi-asserted-by":"crossref","unstructured":"Warren C. J., Van Doorslaer K., Pandey A., Espinosa J. M.& Pyeon D. Role of the host restriction factor APOBEC3 on papillomavirus evolution. Virus Evol. 1, (2015).","DOI":"10.1093\/ve\/vev015"},{"key":"34752_CR11","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1128\/JVI.02383-14","volume":"89","author":"CJ Warren","year":"2015","unstructured":"Warren, C. J. et al. APOBEC3A functions as a restriction factor of human papillomavirus. J. Virol. 89, 688\u2013702 (2015).","journal-title":"J. Virol."},{"key":"34752_CR12","doi-asserted-by":"publisher","first-page":"e1000367","DOI":"10.1371\/journal.ppat.1000367","volume":"5","author":"P Jern","year":"2009","unstructured":"Jern, P., Russell, R. A., Pathak, V. K. & Coffin, J. M. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 5, e1000367 (2009).","journal-title":"PLoS Pathog."},{"key":"34752_CR13","doi-asserted-by":"publisher","first-page":"e1004281","DOI":"10.1371\/journal.ppat.1004281","volume":"10","author":"EY Kim","year":"2014","unstructured":"Kim, E. Y. et al. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. PLoS Pathog. 10, e1004281 (2014).","journal-title":"PLoS Pathog."},{"key":"34752_CR14","doi-asserted-by":"publisher","first-page":"e1005646","DOI":"10.1371\/journal.ppat.1005646","volume":"12","author":"KA Delviks-Frankenberry","year":"2016","unstructured":"Delviks-Frankenberry, K. A. et al. Minimal contribution of APOBEC3-induced G-to-A hypermutation to HIV-1 recombination and genetic variation. PLoS Pathog. 12, e1005646 (2016).","journal-title":"PLoS Pathog."},{"key":"34752_CR15","doi-asserted-by":"publisher","first-page":"e01498","DOI":"10.1016\/j.heliyon.2019.e01498","volume":"5","author":"N Mohammadzadeh","year":"2019","unstructured":"Mohammadzadeh, N. et al. Role of co-expressed APOBEC3F and APOBEC3G in inducing HIV-1 drug resistance. Heliyon 5, e01498 (2019).","journal-title":"Heliyon"},{"key":"34752_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature11881","volume":"494","author":"MB Burns","year":"2013","unstructured":"Burns, M. B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366\u2013370 (2013).","journal-title":"Nature"},{"key":"34752_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"34752_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","volume":"5","author":"C Swanton","year":"2015","unstructured":"Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Disco. 5, 704\u2013712 (2015).","journal-title":"Cancer Disco."},{"key":"34752_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997 (2015).","journal-title":"Nat. Commun."},{"key":"34752_CR20","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1073\/pnas.1424869112","volume":"112","author":"DW Cescon","year":"2015","unstructured":"Cescon, D. W., Haibe-Kains, B. & Mak, T. W. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc. Natl Acad. Sci. USA 112, 2841\u20132846 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"34752_CR21","doi-asserted-by":"publisher","first-page":"e1601737","DOI":"10.1126\/sciadv.1601737","volume":"2","author":"EK Law","year":"2016","unstructured":"Law, E. K. et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci. Adv. 2, e1601737 (2016).","journal-title":"Sci. Adv."},{"key":"34752_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12918","volume":"7","author":"GJ Starrett","year":"2016","unstructured":"Starrett, G. J. et al. The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. Nat. Commun. 7, 12918 (2016).","journal-title":"Nat. Commun."},{"key":"34752_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0572-5","volume":"18","author":"Y Du","year":"2018","unstructured":"Du, Y. et al. APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study. Cancer Cell Int. 18, 78 (2018).","journal-title":"Cancer Cell Int."},{"key":"34752_CR24","doi-asserted-by":"publisher","first-page":"e0230261","DOI":"10.1371\/journal.pone.0230261","volume":"15","author":"YS Kim","year":"2020","unstructured":"Kim, Y. S. et al. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer. PLoS ONE 15, e0230261 (2020).","journal-title":"PLoS ONE"},{"key":"34752_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00493-9","volume":"8","author":"TW Chen","year":"2017","unstructured":"Chen, T. W. et al. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nat. Commun. 8, 465 (2017).","journal-title":"Nat. Commun."},{"key":"34752_CR26","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.celrep.2019.02.028","volume":"26","author":"N Roper","year":"2019","unstructured":"Roper, N. et al. APOBEC mutagenesis and copy-number alterations are drivers of proteogenomic tumor evolution and heterogeneity in metastatic thoracic tumors. Cell Rep. 26, 2651\u20132666 e2656 (2019).","journal-title":"Cell Rep."},{"key":"34752_CR27","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41388-018-0657-6","volume":"38","author":"VL Cannataro","year":"2019","unstructured":"Cannataro, V. L. et al. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene 38, 3475\u20133487 (2019).","journal-title":"Oncogene"},{"key":"34752_CR28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1021\/cb200440y","volume":"7","author":"M Li","year":"2012","unstructured":"Li, M. et al. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem. Biol. 7, 506\u2013517 (2012).","journal-title":"ACS Chem. Biol."},{"key":"34752_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cmdc.201200411","volume":"8","author":"ME Olson","year":"2013","unstructured":"Olson, M. E., Li, M., Harris, R. S. & Harki, D. A. Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold. ChemMedChem 8, 112\u2013117 (2013).","journal-title":"ChemMedChem"},{"key":"34752_CR30","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1021\/acsptsci.1c00091","volume":"4","author":"JJ King","year":"2021","unstructured":"King, J. J. et al. Structure-based design of first-generation small molecule inhibitors targeting the catalytic pockets of AID, APOBEC3A, and APOBEC3B. ACS Pharm. Transl. Sci. 4, 1390\u20131407 (2021).","journal-title":"ACS Pharm. Transl. Sci."},{"key":"34752_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3724\/abbs.2022049","volume":"54","author":"X Yan","year":"2022","unstructured":"Yan, X. et al. Aromatic disulfides as potential inhibitors against interaction between deaminase APOBEC3G and HIV infectivity factor. Acta Biochim. Biophys. Sin. (Shanghai) 54, 725\u2013735 (2022).","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"34752_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1021\/acs.biochem.8b00858","volume":"58","author":"MV Kvach","year":"2019","unstructured":"Kvach, M. V. et al. Inhibiting APOBEC3 activity with single-stranded DNA containing 2\u2019-deoxyzebularine analogues. Biochemistry 58, 391\u2013400 (2019).","journal-title":"Biochemistry"},{"key":"34752_CR33","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/cbic.201900505","volume":"21","author":"MV Kvach","year":"2020","unstructured":"Kvach, M. V. et al. Differential inhibition of APOBEC3 DNA-mutator isozymes by fluoro- and non-fluoro-substituted 2\u2019-deoxyzebularine embedded in single-stranded DNA. Chembiochem 21, 1028\u20131035 (2020).","journal-title":"Chembiochem"},{"key":"34752_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15024","volume":"8","author":"T Kouno","year":"2017","unstructured":"Kouno, T. et al. Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity. Nat. Commun. 8, 15024 (2017).","journal-title":"Nat. Commun."},{"key":"34752_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nsmb.3344","volume":"24","author":"K Shi","year":"2017","unstructured":"Shi, K. et al. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat. Struct. Mol. Biol. 24, 131\u2013139 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"34752_CR36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/pro.4242","volume":"31","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Lan, W., Wang, C. & Cao, C. Two different kinds of interaction modes of deaminase APOBEC3A with single-stranded DNA in solution detected by nuclear magnetic resonance. Protein Sci. 31, 443\u2013453 (2022).","journal-title":"Protein Sci."},{"key":"34752_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04872-8","volume":"9","author":"A Maiti","year":"2018","unstructured":"Maiti, A. et al. Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA. Nat. Commun. 9, 2460 (2018).","journal-title":"Nat. Commun."},{"key":"34752_CR38","doi-asserted-by":"publisher","first-page":"7676","DOI":"10.1093\/nar\/gkz550","volume":"47","author":"WC Solomon","year":"2019","unstructured":"Solomon, W. C. et al. Mechanism for APOBEC3G catalytic exclusion of RNA and non-substrate DNA. Nucleic Acids Res 47, 7676\u20137689 (2019).","journal-title":"Nucleic Acids Res"},{"key":"34752_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/emboj.2008.290","volume":"28","author":"A Furukawa","year":"2009","unstructured":"Furukawa, A. et al. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J. 28, 440\u2013451 (2009).","journal-title":"EMBO J."},{"key":"34752_CR40","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1016\/S0021-9258(19)45812-2","volume":"246","author":"RM Cohen","year":"1971","unstructured":"Cohen, R. M. & Wolfenden, R. Cytidine deaminase from Escherichia coli. Purification, properties and inhibition by the potential transition state analog 3,4,5,6-tetrahydrouridine. J. Biol. Chem. 246, 7561\u20137565 (1971).","journal-title":"J. Biol. Chem."},{"key":"34752_CR41","doi-asserted-by":"publisher","first-page":"9423","DOI":"10.1021\/bi00450a027","volume":"28","author":"L Frick","year":"1989","unstructured":"Frick, L., Yang, C., Marquez, V. E. & Wolfenden, R. Binding of pyrimidin-2-one ribonucleoside by cytidine deaminase as the transition-state analogue 3,4-dihydrouridine and the contribution of the 4-hydroxyl group to its binding affinity. Biochemistry 28, 9423\u20139430 (1989).","journal-title":"Biochemistry"},{"key":"34752_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1006\/jmbi.1994.1018","volume":"235","author":"L Betts","year":"1994","unstructured":"Betts, L., Xiang, S., Short, S. A., Wolfenden, R. & Carter, C. W. Jr. Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. J. Mol. Biol. 235, 635\u2013656 (1994).","journal-title":"J. Mol. Biol."},{"key":"34752_CR43","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1021\/bi00013a010","volume":"34","author":"DC Carlow","year":"1995","unstructured":"Carlow, D. C., Smith, A. A., Yang, C. C., Short, S. A. & Wolfenden, R. Major contribution of a carboxymethyl group to transition-state stabilization by cytidine deaminase: mutation and rescue. Biochemistry 34, 4220\u20134224 (1995).","journal-title":"Biochemistry"},{"key":"34752_CR44","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1021\/bi00014a003","volume":"34","author":"S Xiang","year":"1995","unstructured":"Xiang, S., Short, S. A., Wolfenden, R. & Carter, C. W. Jr. Transition-state selectivity for a single hydroxyl group during catalysis by cytidine deaminase. Biochemistry 34, 4516\u20134523 (1995).","journal-title":"Biochemistry"},{"key":"34752_CR45","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1021\/bi951498y","volume":"35","author":"DC Carlow","year":"1996","unstructured":"Carlow, D. C., Short, S. A. & Wolfenden, R. Role of glutamate-104 in generating a transition state analogue inhibitor at the active site of cytidine deaminase. Biochemistry 35, 948\u2013954 (1996).","journal-title":"Biochemistry"},{"key":"34752_CR46","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1021\/bi963091e","volume":"36","author":"S Xiang","year":"1997","unstructured":"Xiang, S., Short, S. A., Wolfenden, R. & Carter, C. W. Jr. The structure of the cytidine deaminase-product complex provides evidence for efficient proton transfer and ground-state destabilization. Biochemistry 36, 4768\u20134774 (1997).","journal-title":"Biochemistry"},{"key":"34752_CR47","doi-asserted-by":"publisher","first-page":"11873","DOI":"10.1021\/bi980959n","volume":"37","author":"D Carlow","year":"1998","unstructured":"Carlow, D. & Wolfenden, R. Substrate connectivity effects in the transition state for cytidine deaminase. Biochemistry 37, 11873\u201311878 (1998).","journal-title":"Biochemistry"},{"key":"34752_CR48","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1021\/bi971731n","volume":"37","author":"DC Carlow","year":"1998","unstructured":"Carlow, D. C., Short, S. A. & Wolfenden, R. Complementary truncations of a hydrogen bond to ribose involved in transition-state stabilization by cytidine deaminase. Biochemistry 37, 1199\u20131203 (1998).","journal-title":"Biochemistry"},{"key":"34752_CR49","doi-asserted-by":"publisher","first-page":"e1006010","DOI":"10.1371\/journal.ppat.1006010","volume":"12","author":"C Leija","year":"2016","unstructured":"Leija, C. et al. Pyrimidine salvage enzymes are essential for de novo biosynthesis of deoxypyrimidine nucleotides in Trypanosoma brucei. PLoS Pathog. 12, e1006010 (2016).","journal-title":"PLoS Pathog."},{"key":"34752_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ymthe.2019.11.026","volume":"28","author":"A Frances","year":"2020","unstructured":"Frances, A. & Cordelier, P. The emerging role of cytidine deaminase in human diseases: a new opportunity for therapy? Mol. Ther. 28, 357\u2013366 (2020).","journal-title":"Mol. Ther."},{"key":"34752_CR51","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2019.02.012","volume":"176","author":"M Petljak","year":"2019","unstructured":"Petljak, M. et al. Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis. Cell 176, 1282\u20131294 e1220 (2019).","journal-title":"Cell"},{"key":"34752_CR52","doi-asserted-by":"crossref","unstructured":"Buisson R. et al. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science 364, (2019).","DOI":"10.1126\/science.aaw2872"},{"key":"34752_CR53","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.jbc.2021.100909","volume":"297","author":"S Hou","year":"2021","unstructured":"Hou, S. et al. Structural basis of substrate specificity in human cytidine deaminase family APOBEC3s. J. Biol. Chem. 297, 100909 (2021).","journal-title":"J. Biol. Chem."},{"key":"34752_CR54","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1021\/bi011849a","volume":"41","author":"E Johansson","year":"2002","unstructured":"Johansson, E., Mejlhede, N., Neuhard, J. & Larsen, S. Crystal structure of the tetrameric cytidine deaminase from Bacillus subtilis at 2.0 A resolution. Biochemistry 41, 2563\u20132570 (2002).","journal-title":"Biochemistry"},{"key":"34752_CR55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1021\/jm0496279","volume":"48","author":"SJ Chung","year":"2005","unstructured":"Chung, S. J., Fromme, J. C. & Verdine, G. L. Structure of human cytidine deaminase bound to a potent inhibitor. J. Med Chem. 48, 658\u2013660 (2005).","journal-title":"J. Med Chem."},{"key":"34752_CR56","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.1021\/bi060345f","volume":"45","author":"AH Teh","year":"2006","unstructured":"Teh, A. H. et al. The 1.48 A resolution crystal structure of the homotetrameric cytidine deaminase from mouse. Biochemistry 45, 7825\u20137833 (2006).","journal-title":"Biochemistry"},{"key":"34752_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/303041a0","volume":"303","author":"PM Colman","year":"1983","unstructured":"Colman, P. M., Varghese, J. N. & Laver, W. G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303, 41\u201344 (1983).","journal-title":"Nature"},{"key":"34752_CR58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/303035a0","volume":"303","author":"JN Varghese","year":"1983","unstructured":"Varghese, J. N., Laver, W. G. & Colman, P. M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 303, 35\u201340 (1983).","journal-title":"Nature"},{"key":"34752_CR59","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/prot.340140302","volume":"14","author":"JN Varghese","year":"1992","unstructured":"Varghese, J. N., McKimm-Breschkin, J. L., Caldwell, J. B., Kortt, A. A. & Colman, P. M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14, 327\u2013332 (1992).","journal-title":"Proteins"},{"key":"34752_CR60","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1021\/ja963036t","volume":"119","author":"CU Kim","year":"1997","unstructured":"Kim, C. U. et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119, 681\u2013690 (1997).","journal-title":"J. Am. Chem. Soc."},{"key":"34752_CR61","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrd2400","volume":"6","author":"M von Itzstein","year":"2007","unstructured":"von Itzstein, M. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Disco. 6, 967\u2013974 (2007).","journal-title":"Nat. Rev. Drug Disco."},{"key":"34752_CR62","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jmgm.2016.08.004","volume":"69","author":"K Tokuda","year":"2016","unstructured":"Tokuda, K. et al. Hydration of ligands of influenza virus neuraminidase studied by the fragment molecular orbital method. J. Mol. Graph Model 69, 144\u2013153 (2016).","journal-title":"J. Mol. Graph Model"},{"key":"34752_CR63","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1126\/science.2183354","volume":"248","author":"NA Roberts","year":"1990","unstructured":"Roberts, N. A. et al. Rational design of peptide-based HIV proteinase inhibitors. Science 248, 358\u2013361 (1990).","journal-title":"Science"},{"key":"34752_CR64","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1021\/jm00047a001","volume":"37","author":"BD Dorsey","year":"1994","unstructured":"Dorsey, B. D. et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37, 3443\u20133451 (1994).","journal-title":"J. Med. Chem."},{"key":"34752_CR65","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","volume":"92","author":"DJ Kempf","year":"1995","unstructured":"Kempf, D. J. et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl Acad. Sci. USA 92, 2484\u20132488 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"34752_CR66","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1021\/jm9704098","volume":"40","author":"SW Kaldor","year":"1997","unstructured":"Kaldor, S. W. et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40, 3979\u20133985 (1997).","journal-title":"J. Med. Chem."},{"key":"34752_CR67","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","volume":"42","author":"HL Sham","year":"1998","unstructured":"Sham, H. L. et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42, 3218\u20133224 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"key":"34752_CR68","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1021\/jm9802158","volume":"41","author":"SR Turner","year":"1998","unstructured":"Turner, S. R. et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 41, 3467\u20133476 (1998).","journal-title":"J. Med. Chem."},{"key":"34752_CR69","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1128\/AAC.44.8.2093-2099.2000","volume":"44","author":"BS Robinson","year":"2000","unstructured":"Robinson, B. S. et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44, 2093\u20132099 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"34752_CR70","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1128\/AAC.47.10.3123-3129.2003","volume":"47","author":"Y Koh","year":"2003","unstructured":"Koh, Y. et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47, 3123\u20133129 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"34752_CR71","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","volume":"49","author":"S De Meyer","year":"2005","unstructured":"De Meyer, S. et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49, 2314\u20132321 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"34752_CR72","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1021\/jm049560p","volume":"48","author":"DL Surleraux","year":"2005","unstructured":"Surleraux, D. L. et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med Chem. 48, 1813\u20131822 (2005).","journal-title":"J. Med Chem."},{"key":"34752_CR73","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol."},{"key":"34752_CR74","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1107\/S0907444913022750","volume":"69","author":"G Bunkoczi","year":"2013","unstructured":"Bunkoczi, G. et al. Phaser.MRage: automated molecular replacement. Acta Crystallogr D. Biol. Crystallogr 69, 2276\u20132286 (2013).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"34752_CR75","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. Biol. Crystallogr 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"34752_CR76","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1107\/S0907444911001314","volume":"67","author":"GN Murshudov","year":"2011","unstructured":"Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D. Biol. Crystallogr 67, 355\u2013367 (2011).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"34752_CR77","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymeth.2011.07.005","volume":"55","author":"PD Adams","year":"2011","unstructured":"Adams, P. D. et al. The Phenix software for automated determination of macromolecular structures. Methods 55, 94\u2013106 (2011).","journal-title":"Methods"},{"key":"34752_CR78","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol. Crystallogr 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr D Biol. Crystallogr"},{"key":"34752_CR79","doi-asserted-by":"publisher","first-page":"W6","DOI":"10.1093\/nar\/gkm291","volume":"35","author":"A Labarga","year":"2007","unstructured":"Labarga, A., Valentin, F., Anderson, M. & Lopez, R. Web services at the European Bioinformatics Institute. Nucleic Acids Res. 35, W6\u2013W11 (2007).","journal-title":"Nucleic Acids Res."},{"key":"34752_CR80","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J. Comput Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34752-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T00:02:33Z","timestamp":1668902553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34752-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["34752"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-34752-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.08.15.504001","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1964780\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"15 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7117"}}